Response Surface Modeling of Remimazolam and Sevoflurane
Response Surface Model Between Remimazolam and Sevoflurane; Comparison of the Minto and the Greco Model
This prospective randomized open-label study aims to investigate the pharmacodynamic interaction between remimazolam and sevoflurane during general anesthesia using response surface modeling. Although remimazolam has favorable hemodynamic stability compared with propofol, its hypnotic effect may be less predictable and poorly correlated with conventional sedation monitoring indices such as the bispectral index (BIS). In clinical practice, remimazolam and sevoflurane are often combined during induction and maintenance of anesthesia; however, the optimal interaction between these agents remains unclear.
This study will evaluate whether the interaction between remimazolam and sevoflurane is synergistic, additive, or infra-additive using two representative response surface interaction models: the Minto model and the Greco model. BIS values and predicted effect-site concentrations will be analyzed using NONMEM software.
調査の概要
詳細な説明
Remimazolam is a recently developed ultra-short-acting benzodiazepine anesthetic with favorable pharmacokinetic characteristics, including a short context-sensitive decrement time and relatively stable hemodynamics. Despite these advantages, remimazolam may exhibit weaker hypnotic potency and inconsistent correlations with conventional anesthetic depth monitors such as BIS.
In current clinical practice, anesthesiologists frequently combine remimazolam with volatile anesthetics such as sevoflurane during induction or maintenance of anesthesia. However, the pharmacodynamic interaction between remimazolam and sevoflurane has not been fully elucidated.
The present study will investigate the interaction between remimazolam and sevoflurane using response surface modeling. The study will enroll adult patients undergoing elective laparoscopic surgery under general anesthesia. Various combinations of remimazolam infusion rates and end-tidal sevoflurane concentrations will be administered during anesthetic induction. BIS values and predicted effect-site concentrations will be collected and analyzed.
Pharmacodynamic interaction analyses will be performed using NONMEM nonlinear mixed-effects modeling software. Both the Minto interaction model and the Greco interaction model will be applied to determine whether the interaction between remimazolam and sevoflurane is synergistic, additive, or infra-additive.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Hee Young Kim, MD, PhD
- 電話番号：82-55-360-2129
- メール：anekhy@gmail.com
研究場所
-
-
-
Yangsan、韓国、50612
- 募集
- Pusan National University Yangsan Hospital
-
コンタクト：
- Hee Young Kim, MD, PhD
- 電話番号：82-55-360-2129
- メール：anekhy@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Adults aged 20 to 80 years
- Scheduled for elective surgery under general anesthesia at Pusan National University Yangsan Hospital
- American Society of Anesthesiologists (ASA) physical status I or II
- Able to provide written informed consent
Exclusion Criteria:
- Known allergy to remimazolam or sevoflurane
- Renal, hepatic, neuromuscular, or neurological disease
- Use of medications affecting the central nervous system
- Chronic psychoactive drug use
- Ischemic heart disease
- Pregnant women
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：基礎科学
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Remimazolam and Sevoflurane Combination During Anesthetic Induction
Participants undergoing elective surgery under general anesthesia will receive varying combinations of remimazolam and sevoflurane during anesthetic induction to evaluate pharmacodynamic interactions using response surface modeling.
|
Remimazolam will be administered at infusion rates ranging from 0 to 6 mg/kg/h using an infusion pump with pharmacokinetic simulation software.
Sevoflurane will be administered by inhalation with targeted end-tidal concentrations between 0 and 2 vol%.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Interaction coefficient (α) between remimazolam and sevoflurane derived from the Minto response surface model
時間枠：During anesthetic induction
|
The interaction coefficient (α) describing the pharmacodynamic interaction between remimazolam effect-site concentration and end-tidal sevoflurane concentration will be estimated using the Minto response surface model based on BIS values collected during anesthetic induction.
|
During anesthetic induction
|
|
Interaction parameter between remimazolam and sevoflurane derived from the Greco response surface model
時間枠：During anesthetic induction
|
The pharmacodynamic interaction parameter describing the interaction between remimazolam effect-site concentration and end-tidal sevoflurane concentration will be estimated using the Greco response surface model based on BIS values collected during anesthetic induction.
|
During anesthetic induction
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
BIS response according to hypnotic combinations
時間枠：During anesthetic induction
|
Bispectral Index (BIS) values will be continuously recorded during anesthetic induction according to predefined combinations of remimazolam effect-site concentration and end-tidal sevoflurane concentration.
The BIS is a processed electroencephalographic monitoring scale ranging from 0 to 100, where lower values indicate deeper levels of hypnosis and higher values indicate lighter levels of sedation or consciousness.
|
During anesthetic induction
|
|
Loss of consciousness (LOC)
時間枠：During anesthetic induction
|
Time to loss of consciousness during induction
|
During anesthetic induction
|
|
Recovery of consciousness (ROC)
時間枠：During emergence from anesthesia
|
Time to recovery of consciousness
|
During emergence from anesthesia
|
|
Heart rate
時間枠：Intraoperative period
|
Heart rate (beats per minute) will be recorded at 5-minute intervals during the intraoperative period.
|
Intraoperative period
|
|
Systolic blood pressure
時間枠：Intraoperative period
|
Systolic blood pressure (mmHg) will be recorded at 5-minute intervals during the intraoperative period.
|
Intraoperative period
|
|
Mean blood pressure
時間枠：Intraoperative period
|
Mean blood pressure (mmHg) will be recorded at 5-minute intervals during the intraoperative period.
|
Intraoperative period
|
|
Cardiac output
時間枠：Intraoperative period
|
Cardiac output (L/min) will be recorded at 5-minute intervals during the intraoperative period.
|
Intraoperative period
|
|
Cardiac index
時間枠：Intraoperative period
|
Cardiac index (L/min/m²) will be recorded at 5-minute intervals during the intraoperative period.
|
Intraoperative period
|
|
Stroke volume variation
時間枠：Intraoperative period
|
Stroke volume variation (%) will be recorded at 5-minute intervals during the intraoperative period.
|
Intraoperative period
|
|
Pulse pressure variation
時間枠：Intraoperative period
|
Pulse pressure variation (%) will be recorded at 5-minute intervals during the intraoperative period.
|
Intraoperative period
|
|
Peripheral oxygen saturation
時間枠：Intraoperative period
|
Peripheral oxygen saturation (%) will be recorded at 5-minute intervals during the intraoperative period.
|
Intraoperative period
|
協力者と研究者
捜査官
- 主任研究者：Hee Young Kim, MD, PhD、Pusan National University Yangsan Hospital, Yangsan, South Korea
出版物と役立つリンク
一般刊行物
- Choe S, Choi BM, Lee YH, Lee SH, Lee EK, Kim KS, Noh GJ. Response surface modelling of the pharmacodynamic interaction between propofol and remifentanil in patients undergoing anaesthesia. Clin Exp Pharmacol Physiol. 2017 Jan;44(1):30-40. doi: 10.1111/1440-1681.12677.
- Jeon S, Kwon JY, Kim HK, Kim TK. Synergism between rocuronium and cisatracurium: comparison of the Minto and Greco interaction models. Korean J Anesthesiol. 2016 Aug;69(4):341-9. doi: 10.4097/kjae.2016.69.4.341. Epub 2016 Jun 22.
- Byung-Moon Choi: An overview of pharmacodynamic drug interaction with isobole and response surface model in anesthesia. APM 2016; 11: 1-13
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。